Glaxo Considers Developing Gonorrhea Vaccine as Threat Rises
- Drugmaker has also discussed meningitis vaccine’s potential
- Sexually transmitted disease gains resistance, spreads quickly
This article is for subscribers only.
GlaxoSmithKline Plc is considering whether to develop a new vaccine against a sexually-transmitted infection that’s threatening to become unstoppable.
The company is already in discussions with regulators about how the label on Bexsero, its vaccine that prevents a form of meningitis, could be expanded to include gonorrhea, an age-old disease that’s becoming harder to treat, according to Emmanuel Hanon, head of research and development at Glaxo’s vaccine unit. The U.K. drugmaker is also looking at the possibility of developing a vaccine targeted specifically against gonorrhea, which might be more effective, he said.